立体定向消融放疗治疗肺复发寡转移NSCLC的生存及调节性T细胞预后价值
这项前瞻性观察队列研究纳入63例肺复发寡转移NSCLC患者,所有转移灶均接受SABR,并在治疗前3天检测外周血免疫细胞比例。中位随访19.1个月,1年、2年、3年OS率分别为84.3%、63.4%、44.0%,Treg水平高者OS和PFS更差,且Treg是OS和PFS的独立预测因素。
要点
- 肺复发寡转移NSCLC全病灶SABR后1年OS率84.3%,3年OS率44.0%。
- Treg水平是OS和PFS的独立预测因素。
核心结论
- Treg水平对肺复发寡转移NSCLC接受SABR治疗的患者具有独立预后价值。
- 高Treg患者OS和PFS更差,可能需要额外治疗。
研究设计与样本
- 前瞻性观察队列研究,纳入63例寡转移NSCLC患者,所有转移灶均接受SABR。
- 治疗开始前3天采集外周血,用流式细胞术检测Treg、B细胞、NK细胞、γδT细胞、CD8+CD28+ T细胞和CD8+CD28- T细胞比例。
- 采用Kaplan-Meier法估计OS和PFS,Cox比例风险回归评估预后因素。
主要发现
- 中位随访19.1个月,1年、2年、3年OS率分别为84.3%、63.4%、44.0%。
- 1年、2年、3年PFS率分别为55.2%、30.9%、25.7%。
- 1年局部控制率96.7%,2年和3年均为92.7%。
关键数值与推荐
- Treg定义为CD4+CD25+CD127low细胞。
临床怎么用
- 对肺复发寡转移NSCLC患者,SABR可实现较好的局部控制和生存。
- 治疗前检测外周血Treg水平可能有助于识别预后较差的患者。
- 高Treg患者可能需要考虑额外的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated survival of patients with pulmonary recurrence-based oligometastatic non-small cell lung cancer (NSCLC) whose lesions were all treated with stereotactic ablative radiation therapy (SABR) and the prognostic value of peripheral immune cells. METHODS AND MATERIALS: In this prospective observational cohort study, we prospectively enrolled 63 patients with oligometastatic NSCLC, for whom all metastases were treated with SABR. Peripheral blood samples were collected 3 days before treatment began, and flow cytometry was used to identify proportions of regulatory T cells (Tregs; CD4+CD25+CD127low), B cells, NK cells, γδT cells, CD8+CD28+ T cells, and CD8+CD28- T cells. Overall survival (OS) and progression-free survival (PFS) was estimated by the Kaplan-Meier method, and the potential prognostic value of clinicopathologic factors was evaluated by Cox proportional hazards regression. RESULTS: At a median follow-up time of 19.1 months, estimated OS rates were 84.3% at 1 year, 63.4% at 2 years, and 44.0% at 3 years; corresponding PFS rates were 55.2%, 30.9%, and 25.7%. Estimated local control rates were 96.7% at 1 year and 92.7% at both 2 years and 3 years. Patients with high numbers of Tregs had poorer OS and PFS than did those with low numbers of Tregs (OS: 16.1 months vs not reached, P = .006; PFS: 11.0 vs 21.7 months, P = .013). Treg level was found to be an independent predictor of both OS and PFS in multivariate analyses (OS: hazard ratio 2.68, P = .038; PFS: hazard ratio 2.35, P = .011). CONCLUSIONS: Our results revealed the independent prognostic value of Tregs in patients treated with SABR for pulmonary recurrence-based oligometastatic NSCLC. Additional treatments may be needed for patients with oligometastatic NSCLC and poor outcomes.
引用
- Liu C, Sun B, Hu X, et al. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells. Int J Radiat Oncol Biol Phys. 2019. PMID: 31437470. doi:10.1016/j.ijrobp.2019.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。